Long COVID Research

$15,000 of $80,100 raised
The Beljanski Foundation is sponsoring a new clinical trial for patients with Long COVID because of the urgent need for a new and successful treatment. Anecdotal reports from patients experiencing lingering symptoms from an infection with SARS-CoV-2 started to emerge shortly after the beginning of the pandemic, and the term “Long COVID” was coined to name this condition and alert the scientific community. Upwards of 65 million people worldwide are now suffering from this condition. The goal is to test whether the administration of a special preparation of small RNA fragments, originally developed by Dr. Mirko Beljanski, will work by stimulating stem cells in the bone marrow to produce new immune cells. Previous research conducted on this special preparation at Cancer Treatment Centers of America confirmed its safety and effectiveness for treating thrombocytopenia (low platelets) caused by chemotherapy. Thrombocytopenia has been seen in a significant number of Long COVID patients, and low platelets are associated with fatigue – a major symptom of Long COVID. The trial will also reveal the potential of the RNA fragments to re-balance immunity in these patients.
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.
Billing Details


Donation Total: $50.00 One Time

Privacy Preference Center